News

MMS Announces Key Executive Appointment to Support Company’s Next Stage of Growth

MMS Announces Key Executive Appointment to Support Company's Next Stage of Growth

CANTON, Mich. (8/30/2022) – MMS Holdings Inc. (MMS) – a leading contract research organization (CRO) – announced the appointment of Kelly J. Hill to Chief Strategy Officer. This appointment reflects the company’s accelerating growth as it continues to deliver data-focused clinical research services.

A long-time member of MMS’ executive leadership team, Hill brings more than 20 years of business leadership and has helped the company grow from its inception to a global company of over 900 colleagues.

In her new role, Hill will lead overall corporate strategy, producing long-term, sustainable success and ensuring the achievement of the company’s goals. In addition, she will champion the company’s partnerships and alliances.

“I’m grateful for the opportunity to oversee our strategy at such an exciting time for our company,” said Hill. “Building on a strong foundation of great people, processes, and exceptional customer service, we will continue to expand our award-winning services in support of high-impact clinical research and successful therapy approvals, which is of top importance to every member of our global team.”

This appointment comes as MMS announced its partnership with private equity firm Lindsay Goldberg, which completed its investment in the company in late June.

“The new appointment of Kelly to Chief Strategy Officer and our recent partnership with Lindsay Goldberg puts us in a great position to continue assisting our clients in developing life-changing therapies and bringing them to patients,” said Dr. Uma Sharma, Chief Executive Officer. “Kelly has been a strategic right hand to me at MMS, and with our growth, I look forward to her insights and continued leadership in the years ahead.”

ABOUT MMS
MMS Holdings (MMS) is an innovative, data-focused CRO that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, technology-enabled services, and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating. Visit mmsholdings.com to learn more.

Media Contact
Avery Zimmerman

media@mmsholdings.com

Back to MMS News